Maintenance treatment for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have already completed at least 6 cycles of first-line chemotherapy plus an immunotherapy drug (e.g., pembrolizumab or dostarlimab) for your endometrial cancer.
- Your cancer has not grown or spread after that initial treatment, and you can start the study drug within 3 to 9 weeks of finishing it.
- Your endometrial cancer is of certain types (like endometrioid, serous, clear cell, or carcinosarcoma) and is either newly diagnosed at stage III/IV, or has returned after a treatment break.
- Your tumor has a specific marker called MMR-proficient or MSS.
- You are physically active enough for daily activities (ECOG score 0 or 1) and do not have serious lung, heart, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
This trial compares continuing immunotherapy (pembrolizumab or dostarlimab) as maintenance therapy versus stopping it in people with advanced or recurrent endometrial cancer who have already completed standard chemotherapy and immunotherapy. The goal is to see if continuing improves survival.
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.